Skip to Main Content

Paper Details

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Journal of Clinical Oncology
122
2023
Anti-B-cell Maturation Antigen, Chimeric Antigen Receptor, Ciltacabtagene, Patients, Relapsed/Refractory Multiple Myeloma, anti-CD38, cilta, ciltacabtagene, cytokine, cytokine release syndrome, multiple myeloma, parkinsonism, patient, patients, plasmacytomas, relapsed
Author NameAffiliation
Alexander Keith StewartUniversity Health Network and the Princess Margaret Cancer Centre
Andrzej JakubowiakUniversity of Chicago
Sundar JagannathMount Sinai Medical Center
  • 1 - 3

Datasets

Release 1.2